Disparities in Asthma, Allergic Diseases, and Immunologic Diseases (AAN)

Price: FREE for members and non-members

Session recorded on July 16, 2024
Speaker: Nancy Joseph, DO

Asthma and allergy treatment has seen remarkable innovation in the last 25 years, but this progress is still not reaching everyone. More than 25 million Americans have asthma and 50+ million have allergies. These conditions disproportionately impact Black, Hispanic/Latino and Native American communities. Social, economic, and environmental factors often play a key role in causing asthma and allergy disparities. Join us as we explore disparities in allergy, asthma and immunologic diseases and how to best help under-resourced communities. In this activity, Dr. Nancy Joseph will discuss the health disparities statistics, the impact these disparities have on allergic and immunologic diseases and potential interventions and resources.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).

Explore other archived clinical webinars here.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

Upon completion of this activity learners should be able to:

1.    Cite the statistics on disparities in asthma, allergic and immunologic diseases.
2.    Examine the impact health disparities have on patients living with asthma, allergic and immunologic diseases.
3.    Develop an inclusive treatment plan with community resources and possible interventions.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. 

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
07/16/2024
Course expires: 
12/31/2025
Rating: 
0

All identified relevant financial relationships with ineligible companies have been mitigated.

Speaker:
Nancy Joseph, DO
No identified relevant finanical relationships with ineligible companies to disclose

Moderator:
Catherine Blackwell, Allergy Asthma Network (AAN)
No identified relevant finanical relationships with ineligible companies to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.